omeprazole has been researched along with levonorgestrel in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Fuchs, W; Klotz, U; Sennewald, R | 1 |
| Mansmann, U; Roots, I; Rost, KL | 1 |
| Laine, K; Palovaara, S; Tybring, G | 1 |
| Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W | 1 |
1 review(s) available for omeprazole and levonorgestrel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for omeprazole and levonorgestrel
| Article | Year |
|---|---|
Lansoprazole does not affect the bioavailability of oral contraceptives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Biological Availability; Chromatography, High Pressure Liquid; Contraceptives, Oral; Cross-Over Studies; Estradiol; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Glucaric Acid; Humans; Hydrocortisone; Lansoprazole; Levonorgestrel; Luteinizing Hormone; Menstrual Cycle; Omeprazole; Progesterone; Proton Pump Inhibitors; Sex Hormone-Binding Globulin; Therapeutic Equivalency | 1994 |
Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Estradiol Congeners; Ethinyl Estradiol; Female; Glucaric Acid; Humans; Hydrocortisone; Lansoprazole; Levonorgestrel; Omeprazole; Placebos; Progesterone Congeners | 1997 |
The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.
Topics: Adolescent; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Contraceptives, Oral, Synthetic; Cross-Over Studies; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Female; Half-Life; Humans; Levonorgestrel; Lynestrenol; Mixed Function Oxygenases; Omeprazole | 2003 |
Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Topics: Adolescent; Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biphenyl Compounds; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Male; Metformin; Middle Aged; Omeprazole; Tetrazoles; Valsartan; Young Adult | 2016 |
4 other study(ies) available for omeprazole and levonorgestrel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |